Journal of Nanomedicine & Nanotechnology

Reduction in the COVID-19 pneumonia case fatality rate by silver nanoparticles: A randomized case study

5^th International Conference on Nanomedicine and Drug Delivery

June 28, 2023 | Webinar

Subhasish Sarkar, Laura Wieler and Oana Vittos

College of Medicine and Sagore Dutta Hospital, Kolkata, India
BHS Medical Solutions GmbH, Remshalden, Germany
Medone Research Ltd., Bucharest, Romania

Keynote: J Nanomed Nanotechnol

Abstract:

There has been a devastating impact on mankind since the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). At present prophylactic vaccination is the only effective way to prevent the progression to severe disease. Oxygen therapy, corticosteroids and anti-thrombotic medicines are the only drugs proven to be effective, but they do not prevent death in severe cases. The antiviral activity of silver nanoparticles (AgNPs) has been investigated against different types of viruses in recent studies. The antiviral activity has been shown in human immunodeficiency virus, influenza virus, hepatitis B virus, monkey-pox virus, herpes simplex virus, caribe virus, and other respiratory viruses, including SARS-CoV-2. This study is the first clinical trial that aimed to prove the antiviral activity of AgNPs in humans. Conducted in India from 2021 to 2022, this investigator-initiated study (IIS) was designed as an open-label, randomized, parallel-group, and included 40 patients diagnosed with moderately severe to severe COVID-19 pneumonia. Significantly higher survival rates (p < 0.05) and significantly lower number of days until supplemental oxygenation was required (p < 0.0001) for patients receiving adjunctive intravenous AgSept® (AgNPs) compared to control. The importance of intravenous AgNP administration in the treatment of virus-induced pneumonia was highlighted in this study, showing the promising effects of using AgNP as a virucide against many virus-induced diseases.
Recent Publications :
1. Sarkar, J., Das, S., Aich, S., Bhattacharyya, P. & Acharya, K. Antiviral potential of nanoparticles for the treatment of Coronavirus infections. J. Trace Elem. Med. Biol. 72, 126977 (2022).
2. Ratan, Z. A. et al. Silver nanoparticles as potential antiviral agents. Pharmaceutics 13, 1–25 (2021).
3. Speshock, J. L., Murdock, R. C., Braydich-Stolle, L. K., Schrand, A. M. & Hussain, S. M. Interaction of silver nanoparticles with Tacaribe virus. J. Nanobiotechnology 8, 1–9 (2010).
4. Morris, D. et al. Antiviral and Immunomodulatory Activity of Silver Nanoparticles in Experimental RSV Infection. Viruses 11, (2019).
5. Allawadhi, P. et al. Silver nanoparticle-based multifunctional approach for combating COVID-19. Sensors Int. 2, (2021).
6. Jeremiah, S. S., Miyakawa, K., Morita, T., Yamaoka, Y. & Ryo, A. Potent antiviral effect of silver nanoparticles on SARS-CoV-2. Biochem. Biophys. Res. Commun. 533, 195– 200 (2020).
7. Zachar, O. Formulations for COVID-19 Early Stage Treatment via Silver Nanoparticles Inhalation Delivery at Home and Hospital. Sci. Prepr. 1–14 (2020).

Biography :

Subhasish Sarkar has expertise in medicine and teaching. He is currently working as a Resident Medical Officer cum Clinical Tutor at the College of Medicine and Sagore Dutta Hospital, India. He is actively involved in indoor, outdoor, and emergency patient management in the Hospital. He regularly performs numerous elective and emergency operations in the hospital. Emergency operations include peptic perforation, acute appendicitis, large bowel and small bowel obstructions, RTA, gunshot or stab injuries etc. Furthermore, he is engaged in teaching the undergraduate students of MBBS in tutorial classes and also takes bedside clinical classes. He encourages them to actively participate in cutting-edge research work for better-serving mankind.